Translate AMICOR contents if you like

Wednesday, March 18, 2020

Favipiravir

Flu drug used in Japan shows promise in treating COVID-19

3D illustration of an RNA virus, influenza, coronavirus.
(Image: © Shutterstock)
A drug used in Japan to treat influenza seems to be effective at treating the novel coronavirus that causes COVID-19, according to news reports.
The antiviral drug, called Favipiravir or Avigan, showed positive outcomes in clinical trials involving 340 individuals in Wuhan and Shenzhen, said Zhang Xinmin, of China's science and technology ministry, The Guardian reported.
"It has a high degree of safety and is clearly effective in treatment," Zhang said Tuesday (March 17), The Guardian reported.
Developed by Fujifilm Toyama Chemical, the antiviral drug is being manufactured by Zhejiang Hisun Pharmaceutical for treating influenza viruses. Last month, the drug reportedly received approval as an experimental treatment for COVID-19 infections, Pharmaceutical Technology reported.
..............
The drug is specifically made to treat RNA viruses like SARS-CoV-2; these are viruses whose main genetic material is RNA, rather than DNA. The drug stops some viruses from replicating by crippling the enzyme (a substance that gets chemical reactions going) called RNA polymerase, which builds RNA. Without that enzyme intact, the virus can't duplicate its genetic material efficiently once inside a host cell, according to an article describing the drug that was published in 2017 in the journal Proceedings of the Japan Academy, Ser. B, Physical and Biological Sciences.

No comments: